HUP0203317A2 - Tricyclic analgesics, pharmaceutical compositions containing them and their use - Google Patents
Tricyclic analgesics, pharmaceutical compositions containing them and their useInfo
- Publication number
- HUP0203317A2 HUP0203317A2 HU0203317A HUP0203317A HUP0203317A2 HU P0203317 A2 HUP0203317 A2 HU P0203317A2 HU 0203317 A HU0203317 A HU 0203317A HU P0203317 A HUP0203317 A HU P0203317A HU P0203317 A2 HUP0203317 A2 HU P0203317A2
- Authority
- HU
- Hungary
- Prior art keywords
- group
- alkyl
- atom
- cycloalkyl
- hydrogen atom
- Prior art date
Links
- 229940035676 analgesics Drugs 0.000 title abstract 2
- 239000000730 antalgic agent Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 101100167062 Caenorhabditis elegans chch-3 gene Proteins 0.000 abstract 1
- 101100134925 Gallus gallus COR6 gene Proteins 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000004946 alkenylalkyl group Chemical group 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 208000004296 neuralgia Diseases 0.000 abstract 1
- 208000021722 neuropathic pain Diseases 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
- -1 where the azalkyl- Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/20—Spiro-condensed ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
A találmány tárgya triciklusos analgetikumok, amelyek (I) általánosképletű vegyületet vagy gyógyászatilag elfogadható sóit tartalmazzák.Az (I) általános képletben R1 jelentése hidrogénatom vagyhidroxilcsoport; R2 jelentése hidrogénatom vagy hidroxilcsoport; vagyR1 és R2 együtt oxigénatomot képez; A jelentése vegyértékvonal, CH2,CHCH3, CH2CH2 vagy C(CH3)2; R3 és R4 jelentése azonos vagy különböző,és jelentésük hidrogén- vagy halogénatom, 1-6 szénatomos alkil-, 1-4szénatomos alkoxi-, trifluor-metil-, nitro-, COR6, COOR6 vagy NR6R7képletű csoport, ahol R6 és R7 azonos vagy különböző, és jelentésükhidrogénatom, 1-6 szénatomos alkil- vagy benzilcsoport; R5 jelentésehidrogénatom, 1-6 szénatomos alkil-, 2-6 szénatomos alkenil-, 3-6szénatomos cikloalkil-, (O=C)-1-6 szénatomos alkil-, (O=C)-2-6szénatomos alkenil-, (O=C)-3-6 szénatomos cikloalkil-csoport, ahol azalkil-, alkenil- és cikloalkilcsoport 1, 2 vagy 3 halogénatommal, 3-6szénatomos cikloalkil-, fenil- vagy szubsztituált fenilcsoporttallehet szubsztituálva. A találmány szerinti vegyületek neuropátiásfájdalom és más központi idegrendszeri rendellenességek kezelésérehasználhatók. A találmány kiterjed a vegyületeket tartalmazógyógyszerkészítményekre is. ÓThe subject of the invention is tricyclic analgesics, which contain a compound of the general formula (I) or its pharmaceutically acceptable salts. In the general formula (I), R1 is a hydrogen atom or a hydroxyl group; R 2 is a hydrogen atom or a hydroxyl group; orR1 and R2 together form an oxygen atom; A is a valence line, CH 2 , CHCH 3 , CH 2 CH 2 or C(CH 3 ) 2 ; R3 and R4 are the same or different, and they mean a hydrogen or halogen atom, a C1-C6 alkyl, a C1-C4 alkoxy, trifluoromethyl, nitro, COR6, COOR6 or NR6R7 group, where R6 and R7 are the same or different , and mean a hydrogen atom, a C1-C6 alkyl or benzyl group; R5 is a hydrogen atom, C1-C6 alkyl, C2-C6 alkenyl, C3-C6 cycloalkyl, (O=C)-C1-C6 alkyl, (O=C)-2-C6 alkenyl, (O =C)-3-6 carbon atom cycloalkyl group, where the azalkyl-, alkenyl- and cycloalkyl group can be substituted with 1, 2 or 3 halogen atoms, 3-6 carbon atom cycloalkyl-, phenyl- or substituted phenyl group. The compounds according to the invention can be used to treat neuropathic pain and other central nervous system disorders. The invention also covers pharmaceutical preparations containing the compounds. HE
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13786899P | 1999-06-07 | 1999-06-07 | |
| PCT/EP2000/005783 WO2000075116A2 (en) | 1999-06-07 | 2000-06-07 | Tricyclic analgesics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUP0203317A2 true HUP0203317A2 (en) | 2003-02-28 |
Family
ID=22479397
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0203317A HUP0203317A2 (en) | 1999-06-07 | 2000-06-07 | Tricyclic analgesics, pharmaceutical compositions containing them and their use |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP1235808A2 (en) |
| JP (1) | JP2003513006A (en) |
| KR (1) | KR20020010923A (en) |
| CN (1) | CN1635998A (en) |
| AP (1) | AP2001002356A0 (en) |
| AU (1) | AU6428400A (en) |
| BG (1) | BG106162A (en) |
| BR (1) | BR0011427A (en) |
| CA (1) | CA2376076A1 (en) |
| EA (1) | EA200101117A1 (en) |
| HR (1) | HRP20010913A2 (en) |
| HU (1) | HUP0203317A2 (en) |
| IL (1) | IL146755A0 (en) |
| IS (1) | IS6175A (en) |
| MA (1) | MA26795A1 (en) |
| MX (1) | MXPA01012694A (en) |
| NO (1) | NO20015966L (en) |
| PL (1) | PL357340A1 (en) |
| SK (1) | SK17512001A3 (en) |
| TR (1) | TR200103531T2 (en) |
| WO (1) | WO2000075116A2 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030045449A1 (en) * | 2001-08-15 | 2003-03-06 | Pfizer, Inc. | Pharmaceutical combinations for the treatment of neurodegenerative diseases |
| FR2915099B1 (en) * | 2007-04-19 | 2009-06-05 | Sanofi Aventis Sa | USE OF 4-CYCLOPROPYLMETHOXY-N- (3,5-DICHLORO-1-OXYDO-PYRIDIN-4-YL) -5- (METHOXY) PYRIDINE-2-CARBOXAMIDE FOR THE TREATMENT OF CRANIAL TRAUMATISM |
| WO2012106499A1 (en) * | 2011-02-02 | 2012-08-09 | Vertex Pharmaceuticals Incorporated | Pyrrolopyrazine-spirocyclic piperidine amides as modulators of ion channels |
| GB201416346D0 (en) * | 2014-09-16 | 2014-10-29 | Shire Internat Gmbh | Spirocyclic derivatives |
| CN115872873A (en) * | 2022-12-29 | 2023-03-31 | 上海泰坦科技股份有限公司 | Recrystallization purification method of bis (2-bromoethyl) amine hydrobromide |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8917069D0 (en) * | 1989-07-26 | 1989-09-13 | Merck Sharp & Dohme | Therapeutic agents |
| IL96507A0 (en) * | 1989-12-08 | 1991-08-16 | Merck & Co Inc | Nitrogen-containing spirocycles and pharmaceutical compositions containing them |
| DK0681571T3 (en) * | 1993-01-28 | 1998-11-23 | Merck & Co Inc | Spiro-substituted azacyclic compounds as tachykinin receptor antagonists |
| US5439914A (en) * | 1994-02-18 | 1995-08-08 | Merck & Co., Inc. | Spirocycles |
| WO1998025604A1 (en) * | 1996-12-13 | 1998-06-18 | Merck & Co., Inc. | Spiro-substituted azacycles as modulators of chemokine receptor activity |
| US6013644A (en) * | 1997-12-12 | 2000-01-11 | Merck & Co., Inc. | Spiro-substituted azacycles as modulators of chemokine receptor activity |
-
2000
- 2000-06-07 IL IL14675500A patent/IL146755A0/en unknown
- 2000-06-07 CA CA002376076A patent/CA2376076A1/en not_active Abandoned
- 2000-06-07 WO PCT/EP2000/005783 patent/WO2000075116A2/en not_active Application Discontinuation
- 2000-06-07 JP JP2001501597A patent/JP2003513006A/en active Pending
- 2000-06-07 HU HU0203317A patent/HUP0203317A2/en unknown
- 2000-06-07 SK SK1751-2001A patent/SK17512001A3/en unknown
- 2000-06-07 EP EP00951290A patent/EP1235808A2/en not_active Withdrawn
- 2000-06-07 AU AU64284/00A patent/AU6428400A/en not_active Abandoned
- 2000-06-07 AP APAP/P/2001/002356A patent/AP2001002356A0/en unknown
- 2000-06-07 KR KR1020017015730A patent/KR20020010923A/en not_active Application Discontinuation
- 2000-06-07 BR BR0011427-8A patent/BR0011427A/en not_active IP Right Cessation
- 2000-06-07 PL PL00357340A patent/PL357340A1/en not_active Application Discontinuation
- 2000-06-07 MX MXPA01012694A patent/MXPA01012694A/en unknown
- 2000-06-07 CN CNA008086427A patent/CN1635998A/en active Pending
- 2000-06-07 TR TR2001/03531T patent/TR200103531T2/en unknown
- 2000-06-07 EA EA200101117A patent/EA200101117A1/en unknown
-
2001
- 2001-11-23 IS IS6175A patent/IS6175A/en unknown
- 2001-11-30 BG BG106162A patent/BG106162A/en unknown
- 2001-11-30 MA MA26431A patent/MA26795A1/en unknown
- 2001-12-06 NO NO20015966A patent/NO20015966L/en not_active Application Discontinuation
- 2001-12-07 HR HR20010913A patent/HRP20010913A2/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| IS6175A (en) | 2001-11-23 |
| WO2000075116A2 (en) | 2000-12-14 |
| MA26795A1 (en) | 2004-12-20 |
| CA2376076A1 (en) | 2000-12-14 |
| HRP20010913A2 (en) | 2003-04-30 |
| AU6428400A (en) | 2000-12-28 |
| AP2001002356A0 (en) | 2001-12-31 |
| MXPA01012694A (en) | 2003-10-15 |
| CN1635998A (en) | 2005-07-06 |
| NO20015966D0 (en) | 2001-12-06 |
| NO20015966L (en) | 2001-12-06 |
| TR200103531T2 (en) | 2002-06-21 |
| BR0011427A (en) | 2002-03-26 |
| JP2003513006A (en) | 2003-04-08 |
| EA200101117A1 (en) | 2002-06-27 |
| KR20020010923A (en) | 2002-02-06 |
| BG106162A (en) | 2002-05-31 |
| SK17512001A3 (en) | 2002-11-06 |
| WO2000075116A3 (en) | 2002-07-04 |
| PL357340A1 (en) | 2004-07-26 |
| EP1235808A2 (en) | 2002-09-04 |
| IL146755A0 (en) | 2002-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0002476A2 (en) | Amine compounds, their production and use | |
| HUP0105154A2 (en) | Use of anticonvulsant derivatives for treating cluster headaches | |
| HUP0301269A2 (en) | Phthalazinone derivatives and pharmaceutical compositions containing them | |
| HUP0203971A2 (en) | Imidazoimidazoles and triazoles as anti-inflammatory agents and pharmaceutical compositions containing them and their use | |
| DE69923849D1 (en) | QUINOLIN-2-ON DERIVATIVES USE AS ANTICROPHOSIS | |
| HUP0500573A2 (en) | Triphenyl-ethylene derivatives as selective estrogen receptor modulators and pharmaceutical compositions containing the same | |
| HUP0003644A2 (en) | 2,3-diaryl-pyrazolo[1,5-b]pyridazine derivatives, their preparation and their use in pharmaceutical compositions as cyclooxygenase 2 (cox-2) inhibitors | |
| HUP0300207A2 (en) | 1,2,3,4-tetrahydroisquinoline derivatives, pharmaceutical compositions containing them and their preparation processes | |
| HUP0002960A2 (en) | Aryloxyarylsulfonylamino hydroxamic acid derivatives | |
| HUP9902136A2 (en) | Substituted cyclic amino acid derivatives, use thereof, pharmaceutical compositions containing these compounds | |
| MXPA05007496A (en) | Thienopyrimidinediones and their use in the modulation of autoimmune disease. | |
| HUP0200469A2 (en) | Use of sulfamate derivatives for treating impulse control disorders | |
| HUP0104204A2 (en) | Pyrazolopyridine derivatives as cox-2 inhibitors, process for their preparation and pharmaceutical compositions thereof | |
| BRPI0518233A2 (en) | adjunctive therapy for depression | |
| MY132432A (en) | Aromatic compounds | |
| HUP0103096A2 (en) | Pharmaceutical composition containing 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole in combination with estrogens | |
| HUP0000762A2 (en) | 2-amino-6-(2-substituted-4-phenoxy)-substituted-pyridines, and pharmaceutical compositions containing them | |
| ATE25682T1 (en) | INDOL-3-CARBOXAMIDE DERIVATIVES. | |
| ATE83773T1 (en) | 3(2H)PYRIDAZINONE, PROCESS FOR ITS PREPARATION AND ANTI-SRS-A AGENT CONTAINING IT. | |
| MXPA02001571A (en) | Method of cancer treatment. | |
| RU97117350A (en) | INTIMA HYPERTROPHY INHIBITOR, OXINDOL DERIVATIVE APPLICATION FOR THE INIMA HYPERTROPHY INHIBITOR INHIBITOR, A COMPOSITION FOR INHIBITING INTIMA HYPERTROPHY, PREVENTION AND TREATMENT HYPERT | |
| HUP0203524A2 (en) | 2-(1h-indol-3-yl)-2-oxo-acetamides with antitumor activity, their use and pharmaceutical compositions containing them | |
| HUP0003577A2 (en) | Tetrahydro gamma-carbolines, process for their preparation, their use and pharmaceutical compositions containing them | |
| HUP0203317A2 (en) | Tricyclic analgesics, pharmaceutical compositions containing them and their use | |
| IL110831A0 (en) | Quinazolinone-containing pharmaceutical compositions and methods for the use thereof |